It was nearly a century ago, in 1918, that an influenza pandemic swept the world, killing as many as 40 million people. The “Spanish Flu,” as it was known, ended up causing nearly 675,000 deaths in the U.S., as it was a strain that quickly converted to pneumonia at a time when antibiotic drugs weren’t available.
The Lovelace team has been performing cigarette-smoke inhalation exposure studies for more than 25 years, ranging from characterization of smoke to comparison of whole-body and nose-only exposure systems. We also are experts in measuring the toxicological effects of cigarette smoke inhalation exposure, using a variety of innovative methods and models depending on the needs of the study.
Get an inside look into a 15-year collaboration between the scientists at Lovelace Biomedical and engineers at Capsugel, a company that develops and manufactures dosage forms for the biopharmaceutical and consumer health industries.
The race is on for better therapies to treat pulmonary fibrosis, a chronic lung disease characterized by irreversible scarring of lung tissue. Though the condition is classified as a rare disease, its impact on patients is profound: nearly as many Americans die each year from the most common form of the disease, idiopathic pulmonary fibrosis (IPF), as from breast cancer.
Dr. Barrett explains the drug industry’s challenge to meet clinical endpoints for Alzheimer’s therapies that have shown promise in mice: “Despite researchers’ valiant efforts to stall, slow, or even beat this devastating neurodegenerative condition, there are still no effective drugs available to the estimated 5.4 million Americans with the disease.”
At Lovelace Biomedical, the essential functions of compliance and quality assurance are spearheaded by the passionate Jennifer Cleerdin, Senior Director of Scientific Operations. Since joining Lovelace in 2003, Ms. Cleerdin has developed and implemented a quality process that’s unparalleled in the contract research field.
Albuquerque, N.M., March 8, 2017 – Lovelace Biomedical, a not-for-profit preclinical contract research organization, today announced its participation in and presentation of scientific data at the Society of Toxicology (SOT) 56th Annual Meeting, held March 12 to 16 in Baltimore. This announcement comes on the heels of launching Lovelace Biomedical to partner with companies to cost-effectively and efficiently advance preclinical development of therapeutic compounds and novel technologies, highlighting its shift in focus and expertise in general and specialty toxicology.
As Lovelace Biomedical expands its footprint in toxicology service offerings, some are asking: Why general toxicology, and why now? Here, we get the answers from Dr. Matthew Reed, a board-certified toxicologist and Lovelace’s Vice President of Applied Toxicology and Nonclinical Development
As you prepare to launch ambitious new projects in 2017, I’d like to personally encourage you to explore the wide array of services and expertise Lovelace Biomedical provides in toxicology, pharmacology, formulation and more. While Lovelace is the same not-for-profit CRO you’ve always known—with a deep history of excellence in respiratory research—today, we offer much more.
The Lovelace Respiratory Research Institute, including the commercially-focused CRO arm Lovelace Biomedical, has been a leader in inhalation drug delivery, respiratory disease and development of aerosol formulations for more than 40 years. This year, Lovelace will showcase this broad expertise as the host organization for the 21st Congress of the International Society for Aerosols in […]